GlassScriptPhysician profile
Selin Abraamyan
NPI 1144795899
$7,929.09
in general payments reported to CMS, 2019-2025
33 companies · $1,518 in 2025
The $1,518 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,527 · 2022: $1,561 · 2023: $1,708 · 2024: $1,616 · 2025: $1,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,841.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,745.38 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,498.41 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $661.56 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $570.50 | 2021-2025 | Farxiga, Brilinta, Lokelma |
| Amgen INC. | $511.66 | 2021-2025 | Repatha, Repatha |
| Irhythm Technologies, INC. | $357.65 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $328.61 | 2021-2025 | Lifevest |
| Abiomed | $270.72 | 2024-2025 | Impella |
| Pfizer INC. | $236.05 | 2022-2025 | |
| Amarin Pharma, INC. | $200.72 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $172.33 | 2021-2023 | Xarelto |
| Esperion Therapeutics, INC. | $156.30 | 2021-2024 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $133.49 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $121.93 | 2023-2024 | Amvuttra |
| Heartflow, INC. | $106.37 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $93.07 | 2022-2024 | Watchman Flx, Watchman Access System |
| Edwards Lifesciences Corporation | $92.75 | 2025 | Sapien 3 Ultra Resilia |
| Impulse Dynamics (USA) INC. | $62.54 | 2023 | Optimizer |
| Novo Nordisk INC | $60.79 | 2021 | |
| Lilly USA, LLC | $58.22 | 2024-2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $53.00 | 2023-2025 | Cardiomems |
| Lexicon Pharmaceuticals, INC. | $51.95 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $50.95 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $50.66 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $50.56 | 2023-2025 | Opsumit, Uptravi |
| Depuy Synthes Sales INC. | $47.36 | 2025 | Embotrap |
| Kestra Medical Technology Services, INC. | $37.96 | 2025 | Assure Wcd |
| Lantheus Medical Imaging, INC. | $34.52 | 2022 | |
| Medtronic, INC. | $27.61 | 2023 | Micra |
| Glaxosmithkline, LLC. | $23.59 | 2025 | Shingrix, Arexvy |
| Astellas Pharma US INC | $23.08 | 2021 | |
| Cleerly, INC. | $21.74 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Arbor Pharmaceuticals, INC. | $17.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Selin Abraamyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.